Idera Pharmaceuticals to Present at the Cowen and Company 31st Annual Health Care Conference
CAMBRIDGE, Mass., Feb 28, 2011 (BUSINESS WIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), today announced that it will provide an overview of its drug discovery and development programs targeted to Toll-like Receptors and a general corporate update at the Cowen and Company 31st Annual Health Care Conference on Monday, March 7, 2011 at 10:35 a.m. ET at the Boston Marriott Copley Place in Boston, MA.
The live audio webcast presentation will be available in the Investor section of the company's website at www.iderapharma.com. Archived replays will also be available on the company's site for two weeks following the event. Please log in approximately 10 minutes prior to the presentation to ensure a timely connection.
About Idera Pharmaceuticals, Inc.
Idera Pharmaceuticals is developing drug candidates designed to modulate immune responses through specific Toll-like Receptors for a broad range of diseases, including chronic hepatitis C virus infection, autoimmune and inflammatory diseases, cancer, and respiratory diseases, and for use as vaccine adjuvants. Idera's DNA and RNA chemistry expertise has created a pipeline of compounds for internal development and generates opportunities for multiple collaborative alliances. For more information, visit www.iderapharma.com.
SOURCE: Idera Pharmaceuticals, Inc.
Idera Pharmaceuticals, Inc.
Teri Dahlman, 617-679-5519
tdahlman@iderapharma.com
or
MacDougall Biomedical Communications
Chris Erdman, 781-235-3060
cerdman@macbiocom.com